- Home
- ALXO vs BCAB Comparison
ALXO vs BCAB Comparison
Compare ALXO & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALXO
- BCAB
- Stock Information
- Founded
- ALXO 2015
- BCAB 2007
- Country
- ALXO United States
- BCAB United States
- Employees
- ALXO N/A
- BCAB N/A
- Industry
- ALXO Biotechnology: Pharmaceutical Preparations
- BCAB Medicinal Chemicals and Botanical Products
- Sector
- ALXO Health Care
- BCAB Health Care
- Exchange
- ALXO Nasdaq
- BCAB Nasdaq
- Market Cap
- ALXO 28.3M
- BCAB 27.0M
- IPO Year
- ALXO 2020
- BCAB 2020
- Fundamental
- Price
- ALXO $0.42
- BCAB $0.43
- Analyst Decision
- ALXO Strong Buy
- BCAB Buy
- Analyst Count
- ALXO 6
- BCAB 2
- Target Price
- ALXO $3.54
- BCAB $1.00
- AVG Volume (30 Days)
- ALXO 515.3K
- BCAB 538.7K
- Earning Date
- ALXO 05-08-2025
- BCAB 05-06-2025
- Dividend Yield
- ALXO N/A
- BCAB N/A
- EPS Growth
- ALXO N/A
- BCAB N/A
- EPS
- ALXO N/A
- BCAB N/A
- Revenue
- ALXO N/A
- BCAB $11,000,000.00
- Revenue This Year
- ALXO N/A
- BCAB N/A
- Revenue Next Year
- ALXO N/A
- BCAB N/A
- P/E Ratio
- ALXO N/A
- BCAB N/A
- Revenue Growth
- ALXO N/A
- BCAB N/A
- 52 Week Low
- ALXO $0.44
- BCAB $0.24
- 52 Week High
- ALXO $17.50
- BCAB $3.53
- Technical
- Relative Strength Index (RSI)
- ALXO 31.14
- BCAB 51.43
- Support Level
- ALXO $0.49
- BCAB $0.43
- Resistance Level
- ALXO $0.55
- BCAB $0.58
- Average True Range (ATR)
- ALXO 0.05
- BCAB 0.06
- MACD
- ALXO 0.00
- BCAB 0.00
- Stochastic Oscillator
- ALXO 4.92
- BCAB 45.21
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.